Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - A randomized trial of the German AIO CRC study group

Journal of Clinical Oncology

Volumn 29, Issue 8, 2011, Pages 1050-1058

  Moosmann, Nicolas ^a   Von Weikersthal, Ludwig Fischer ^a   Vehling Kaiser, Ursula ^a   Stauch, Martina ^a   Hass, Holger G ^a   Dietzfelbinger, Herrmann ^a   Oruzio, Daniel ^a   Klein, Stefan ^a   Zellmann, Klaus ^a   Decker, Thomas ^a   Schulze, Mathias ^a   Abenhardt, Wolfgang ^a   Puchtler, Gerhard ^a   Kappauf, Herbert ^a   Mittermüller, Johann ^a   Haberl, Christopher ^a   Schalhorn, Andreas ^a   Jung, Andreas ^a   Stintzing, Sebastian ^a   Heinemann, Volker ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ACNE; ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NAIL; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; POPULATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GERMANY; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952768031     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.1936     Document Type: Article

References (27)

1. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
2. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004 (Pubitemid 41095110)
3. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000 (Pubitemid 30644117)
4. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
5. Kohne CH, van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23: 4856-4865, 2005 (Pubitemid 46223990)
6. Porschen R, Arkenau HT, Kubicka S, et al: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223, 2007 (Pubitemid 47548561)
7. Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al: Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25:4224-4230, 2007 (Pubitemid 47548562)
8. Cassidy J, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012, 2008
9. Bajetta E, Di Bartolomeo M, Mariani L, et al: Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100:279-287, 2004 (Pubitemid 38063635)
10. Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al: A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as firstline therapy for advanced colorectal cancer. Ann Oncol 16:1123-1132, 2005 (Pubitemid 41418315)
11. Moosmann N, Heinemann V: Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Clin Colorectal Cancer 7:110-117, 2008
12. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370:135-142, 2007 (Pubitemid 47042893)
13. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004 (Pubitemid 38944402)
14. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
15. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
16. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515, 2008 (Pubitemid 351325672)
17. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
18. Lievre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008 (Pubitemid 351171687)
19. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
20. Borner MM, Bernhard J, Dietrich D, et al: A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity. Ann Oncol 16:282-288, 2005 (Pubitemid 40309311)
21. Cartwright T, Lopez T, Vukelja SJ, et al: Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5:50-56, 2005
22. Van Cutsem E, Rougier P, Kohne C, et al: A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status. Ann Oncol 20: vii18, 2009 (suppl 7; abstr 6077)
23. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Biomarkers predictive for outcome in patients with metastatic colorectal cancer treated with first-line FOLFOX-4 plus or minus cetuximab: Updated data from the OPUS study. ASCO Gastrointestinal Cancers Symposium 2010 (abstr 428)
24. Maughan T, Adam R, Smith C, et al: Addition of cetuximab to oxaliplatin-based combination chemotherapy in patients with KRAS wild-type advanced colorectal cancer: A randomised superiority trial (MRC COIN). Eur J Cancer 7:4, 2009 (suppl; abstr 6LBA)
25. Adams RA, Meade AM, Madi A, et al: Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100:251-258, 2009
26. Reinacher-Schick A, Kubicka S, Freier W, et al: The combination of bevacizumab with capecitabine/irinotecan or capecitabine/oxaliplatin is highly active in advanced colorectal cancer: A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 26:215s, 2008 (suppl; abstr 4030)
27. Kohne CH, De Greve J, Hartmann JT, et al: Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19:920-926, 2008 (Pubitemid 351627308)